IMM vs IMU, page-11

Market cap:
IMM - $250m
IMU - $1.3b

7 years ago IMU - $10m m/c.

We have been left behind by our peers (not only IMU) on the clinical development front.
Pipeline in a product and Lag pure play obviously doesn't wash in the eyes of market.



AIPAC - agreed with poster 'China partner to develop'
NSCLC and HNC - favourites to develop. But what's the end game - Merck would hold all ace cards and really don't need to over commit- supply agreements keep efti in trials possibly ad-infinitum?
Where's the competitive tension?

Maybe I'm missing something here but not 'feeling the love' or advisory on strategic direction and comms have been p poor of late.

Also poor form imo for chairman to dismiss share price decline to purely geopolitical and other external issues.
I don't want fluff. Take responsibility.

We have been calling for management responsibility for some time now. To make the call re SP was an abrogation of their responsibility for that poor performance IMO. And it sends me a red flag.

Clearly the poorer performing biotechs are going to accelerate their losses, as are we.

Not impressed, and I hate having to say that.